# Abbott to acquire Exact Sciences for $21 billion

Abbott announced a definitive agreement to acquire Exact Sciences for $105 per share, total equity value of approximately $21 billion, adding cancer screening and precision oncology diagnostics.

- Type: Acquisition
- Announced: 2025-11-20
- Where: Abbott Park, Illinois; Madison, Wisconsin, United States
- Value: $21.0B
- Status: announced
- Products: Cologuard, Oncotype DX, liquid biopsy tests
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Abbott](https://endata.com/companies/4479.md) (acquirer)
- [Exact Sciences](https://endata.com/companies/88562.md) (target)

## Sources

- [exactsciences.com](https://www.exactsciences.com/news-events/press-releases/abbott-to-acquire-exact-sciences-a-leader-in-large-and-fast-growing-cancer-screening-and-precision), 2025-11-20: "This acquisition adds a new growth vertical to Abbott’s already high single-digit growth profile."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.